Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL5661 Target Snapshot

Exportin-1 · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
294Compounds
126Assays
4Approved Drugs
178.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Exportin-1 shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt O14980. Start with cancer, then reuse UniProt O14980 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with cancer, then reuse UniProt O14980 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
cancer

Exportin-1 shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with cancer because it currently carries approved-linked support. Linked drugs include SELINEXOR. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Exportin-1 as ChEMBL target CHEMBL5661, mapped to UniProt O14980. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Exportin-1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL5661
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
O14980
Exportin-1
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Exportin-1 is the right protein anchor across sources, using UniProt O14980 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why cancer is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameExportin-1
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtO14980
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelExportin-1
UniProt AccessionO14980
Component TypeProtein
Sequence Length1071 aa

Exportin-1

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Exportin-1, mapped to UniProt O14980. Sequence length is 1071 aa.

Mapped IDO14980
Review nameExportin-1
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Exportin-1 shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugSELINEXOR
Approved-linked Approved
diffuse large B-cell lymphoma
1 linked drug · 1 direct · 1 efficacy
Linked drugSELINEXOR
Approved-linked Approved
multiple myeloma
1 linked drug · 1 direct · 1 efficacy
Linked drugSELINEXOR
Approved-linked Approved
neoplasm
1 linked drug · 1 direct · 1 efficacy
Linked drugSELINEXOR
Late clinical Phase III
acute myeloid leukemia
1 linked drug · 1 direct · 1 efficacy
Linked drugSELINEXOR
Late clinical Phase III
endometrial cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugSELINEXOR
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with cancer because it currently carries approved-linked support. Linked drugs include SELINEXOR. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasecancer
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

4
Approved
1
Phase II
1
Phase I
Assay Mix

Activity Type Distribution

IC50108.0
EC5058.0
KD12.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL486133 9.0 IC50 1.0 Preclinical
CHEMBL129857 8.7 EC50 2.0 Preclinical
CHEMBL5555068 8.4 EC50 4.0 Preclinical
CHEMBL5556912 8.4 EC50 4.0 Preclinical
CHEMBL5559223 8.4 EC50 4.0 Preclinical
CHEMBL3898452 8.3 EC50 5.0 Preclinical
CHEMBL5568605 8.15 EC50 7.0 Preclinical
CHEMBL4088268 8.0 IC50 10.0 Preclinical
CHEMBL5542885 7.96 EC50 11.0 Preclinical
CHEMBL3545185 7.92 EC50 12.0 Approved
Distribution

pChEMBL Value Distribution

12
5.0
11
5.5
30
6.0
13
6.5
10
7.0
15
7.5
7
8.0
1
8.5
1
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

SELINEXOR
CHEMBL3545185
Approved 2019
Properties Compare Identifier
Assay Landscape

Assay Landscape

126
Total Assays
101
Tested Compounds
1
Assay Types
Binding — 126 assays, 101 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 88 84 6.6
single protein format 32 12 6.0
assay format 6 5 5.0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine